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The COVID-19 pandemic revealed a global need for affordable, accessible biologic medicines such as
prophylactic vaccines and antiviral monoclonal antibodies. Indeed, two years after the emergence of SARSCoV-2, access to vaccines and therapeutic proteins is still limited in low- and middle-income countries. Long
development timelines, expensive manufacturing requirements, and stringent storage conditions all contribute to
the high cost of biologic medicines generally. While therapeutic proteins may have higher stability and less
stringent storage requirements than newer modalities like therapeutic RNAs, complex therapeutic proteins like
antibodies are typically produced in mammalian cells, which increase costs due to sterility requirements,
expensive feedstocks, and long cell line development timelines. Additionally, there is limited total global capacity
for manufacturing therapeutic protein in mammalian hosts.
Alternative hosts have potential to increase the accessibility of therapeutic proteins by shortening development
timelines, lowering manufacturing costs, and increasing the global manufacturing capacity. Single-celled
eukaryotes such as yeasts represent a “sweet spot” for protein manufacturing—yeasts grow to high cell
densities on inexpensive feedstocks like bacteria, and can secrete products into the extracellular space like
mammalian cells. One yeast, Komagataella phaffii (Pichia pastoris), is currently used for manufacturing of
insulin and subunit vaccines in LMICs, and has recently been approved by the FDA for the manufacture of
several complex therapeutic proteins, including a monoclonal antibody. Wider adoption of alternative hosts such
as K. phaffii in has been hampered by bespoke manufacturing challenges for unique therapeutic proteins such
as subunit vaccines, and low upstream titers of complex therapeutic proteins with stringent quality requirements
such as monoclonal antibodies.
In this talk, I will discuss engineering efforts to enable and improve the manufacturing of several therapeutic
proteins in K. phaffii. First, we improved the manufacturing of a trivalent subunit protein vaccine for rotavirus by
host-informed product sequence engineering. Recently, we applied both product engineering and host strain
engineering to rapidly develop a subunit vaccine for COVID-19 that can be manufactured at low-cost and at
large scale. I will describe the design of the product, efforts that informed manufacturing scale up, and
preclinical testing of the vaccine product. This product is now manufactured at the Serum Institute of India, and
is currently in clinical trials. Finally, I will discuss how these engineering strategies can be applied to other
needed therapeutics like monoclonal antibodies.

